drugset / Trial / NCT05212584
CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma
NaSequentialOpen-labelTreatment
Summary
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CD7 CAR-T cells in patients with relapsed and/or refractory, high risk hematologic malignancies.
Timeline
- Start
- 2022-07-01
- Primary completion
- 2024-06-30
- Completion
- 2024-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD7 CAR-T cells | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | CD7 CAR-T cells | Cell therapy | 7e+06 cells/kg | Intravenous |